Association of Vitamin D with Inflammatory Bowel Disease Activity in Pediatric Patients

Seyoung Kim,1 Yunkoo Kang,2 Sowon Park,1 Hong Koh,1 and Seung Kim1

1Pediatric Gastroenterology, Hepatology and Nutrition, Severance Pediatric IBD Research Group, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul, Korea
2Department of Pediatrics, Wonju Severance Christian Hospital, Wonju College of Medicine, Yonsei University, Wonju, Korea

ABSTRACT

Background: It has been known that vitamin D level (serum 25[OH]D) has correlation with inflammatory bowel disease (IBD). The purpose of this study is to investigate changes of serum 25[OH]D in pediatric IBD patients according to the disease activity.

Methods: A total of 96 children and adolescent with IBD were enrolled in this retrospective study. Serologic inflammatory markers and clinical disease activity scores of the patients were collected, and their correlations with serum 25[OH]D were analyzed. Seasonal variations of serum 25[OH]D were also investigated both in active disease state and remission state.

Results: Of the 96 patients, 41 (43%) were women and patients with a vitamin D deficiency (< 20 ng/mL) at diagnosis were 77 (80.2%). There was no significant difference between Crohn’s disease and ulcerative colitis for serum 25[OH]D. Serum 25[OH]D was higher in remission group than in active disease group (12.4 [8.8–29] ng/mL vs. 17.9 [12.3–34.4] ng/mL; P < 0.001) and the difference was more significant than other micronutrients. There was no significant difference in serum 25[OH]D concentration between patients with ileal involvement and patients without ileal involvement. There were seasonal variations in the active phase, but there was no significant difference by season in the remission phase.

Conclusion: Serum 25[OH]D is inversely correlated with disease activity in IBD. Monitoring and supplementation is required especially for active disease status and in winter and spring season.

Keywords: Vitamin D; Inflammatory Bowel Disease; Crohn’s Disease; Ulcerative Colitis; Disease Activity; Pediatric

INTRODUCTION

Inflammatory bowel diseases (IBDs), such as Crohn’s disease (CD) and ulcerative colitis (UC), are chronic inflammatory diseases that involve the gastrointestinal tract.1 Although the pathogenesis and etiology of IBD are not well understood, it has been hypothesized that its pathogenesis involves environmental and genetic factors.2 Impaired immunity in response to the intestinal flora and antigens are thought to cause chronic inflammation in the alimentary tracts.2,3
Malnutrition is found in up to 85% of patients with IBD, in the active and remission phases. Micronutrient deficiencies are present in more than half of patients with IBD. The deficiencies are more frequent in CD than in UC and in active disease than in remission. The most common micronutrients deficiencies in IBD are vitamin B12, folate, iron, and especially vitamin D.

Vitamin D is known as the most important regulator of calcium (Ca) and phosphorus (P) metabolism related to bone health but studies suggest the new role of vitamin D in immunomodulation recently, and Vitamin D is even proposed as a treatment for autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, and IBD. Furthermore Ananthakrishnan et al. has reported that vitamin D deficiency may play a role in the increased risk of malignancies in IBD. However, limited studies have been conducted about the relationship between vitamin D and disease activity in IBD over a multi-year period, especially in pediatric patients so far.

Therefore, we aimed to investigate the association of vitamin D with disease activity and clinical course in pediatric patients with IBD.

METHODS

Patients
Our study was performed in the Pediatric Gastroenterology, Hepatology and Nutrition Clinic of Severance Children’s Hospital for patients diagnosed with UC or CD from September 2012 to April 2018.

Patients younger than 19 years of age who were diagnosed with CD or UC according to the Revised Porto Criteria and underwent regular follow-up were included in this study. Patients diagnosed with IBD unclassified, patients who did not undergo blood tests including vitamin D during the active and remission phases, patients with insufficient medical records, and patients with vitamin D supplementation were excluded.

Data collection
The medical records of the enrolled patients were retrospectively analyzed. Clinical records and laboratory test results during the active and remission phases were collected for each patient. We recorded the highest disease activity score and longest duration of remission in cases when there were multiple active phases or remission phases in one patient. In this study, the active phase was defined as when the disease activity score (Pediatric Crohn’s Disease Activity Index [PCDAI] or Pediatric Ulcerative Colitis Activity Index [PUCAI]) was 10 or more. The remission phase was defined as the period when the patient’s clinical symptoms were relieved and the disease active score remained below 10 points for more than 3 months without the use of steroids.

Biochemical assessment
Our registry includes demographic, laboratory, clinical, endoscopic, radiological, and pathological data of the enrolled patients, and it is updated routinely. Clinical records and disease activity scores documented at 2 to 6-month intervals were collected for each patient. Serologic markers of inflammation, including the C-reactive protein (CRP) level, erythrocyte sedimentation rate (ESR), and white blood cell (WBC), as well as levels of serum Ca/P, folate,
vitamin B12, zinc, albumin, pre-albumin, and vitamin D were collected. To evaluate patients’ vitamin D status, the serum level of 25-hydroxyvitamin D $25[\text{OH}]D$ was measured using the liquid chromatography-tandem mass spectrometry in the clinical laboratory.

Patients were classified based on their serum $25[\text{OH}]D$ level. Vitamin D deficiency was defined as a $25[\text{OH}]D$ level < 20 ng/mL, insufficiency as 21–29 ng/mL, and normal or sufficient as > 30 ng/mL.\textsuperscript{10,12}

**Statistical analysis**

Laboratory data for CD and UC, and laboratory data for active and remission phases were analyzed using the Mann-Whitney U test. The changes of active and remission phases in each patient were analyzed using the paired $t$-test. We compared the vitamin D levels of an age-matched healthy control group from the Korea National Health and Nutrition Examination Survey and those of our study patients with IBD by using the Student’s $t$-test. Vitamin D levels in the active and remission phases were compared using the Kruskal-Wallis test for each season (spring, summer, fall, and winter).

All statistical analyses were performed using the SPSS software (version 23.0; IBM Corp., Armonk, NY, USA). The 95% confidence interval is reported where relevant. Two-sided $P$ values of < 0.05 were considered statistically significant.

**Ethics statement**

The protocol of this study was approved by the Institutional Review Board (IRB) of Severance Hospital (IRB approval No. 4-2018-1044). Because this was an observational study without intervention and without the presentation of any identifying data, the committee ruled that informed consent was unnecessary.

**RESULTS**

Ninety-six patients with IBD (72 patients with CD, 24 patients with UC) formed the study population. Table 1 shows the study population’s basic demographics, clinical characteristics, and data on vitamins. There was a significant difference in gender between the patients with CD and those with UC. A higher percentage of man patients had CD, whereas a higher proportion of woman patients had UC.

As shown in Table 2, there was no significant difference between CD and UC for serum $25[\text{OH}]D$. The inflammatory markers were elevated in patients with UC and CD during the
active phase compared to those during the remission phase. Additionally, the inflammatory markers were higher in patients with CD than in those with UC during both phases.

Ca, P, and albumin levels remained relatively unaffected by disease activity in patients with UC. These micronutrients were lower in the active phase and showed a tendency to recover well during the remission phase in patients with CD.

In patients with UC and CD, folate and zinc levels showed a tendency to be dependent on disease activity, as they decreased in the active phase and increased in the remission phase. These micronutrients tended to recover well during the remission phase in patients with UC, but less recovery was shown in patients with CD. Specifically, vitamin B12 was higher in the active phase than in the remission phase.

Vitamin D in patients with UC and CD showed a significant difference according to disease activity. In particular, the vitamin D level was higher in the remission phase than in the active phase, but it remained in “insufficiency” status.

Except for vitamin B12, the other micronutrients showed a tendency to increase significantly in the remission phase than in the active phase according to the paired t-test. Vitamin D showed a larger difference in remission and active phases than other micronutrients when evaluated using fold-change measurements (Fig. 1).

IBD patients in the active phase showed a lower mean vitamin D level than the healthy control group and remission phase group. Vitamin D levels of the remission phase group and control group based on youth in the Korea National Health and Nutrition Examination Survey of 2015 were similar (Fig. 2).

However, there was no statistically significant difference in the vitamin D level during the active phase whether or not IBD involved the ileum (12.45 ng/mL and 11.91 ng/mL, respectively).

Finally, measured vitamin D levels in active phase and remission phase were sub-grouped according to the measured season. There were seasonal variations in the active phase, but there was no significant difference by season in the remission phase (Fig. 3).

### Table 2. Laboratory findings in inflammatory bowel disease patients in active phase and remission phase

| Variables          | Comparison between CD and UC, remission phase | Comparison between CD and UC, active phase | Comparison between active and remission phase |
|--------------------|-----------------------------------------------|-------------------------------------------|-----------------------------------------------|
|                    | CD (n = 72) | UC (n = 24) | P value | CD (n = 72) | UC (n = 24) | P value | CD, UC, remission phase | P value, CD | P value, UC |
| WBC, 10^3/μL       | 6,505      | 6,210      | 0.356   | 8,965      | 7,735      | 0.212   | < 0.001^a              | 0.002^a     |
|                    | (5,182.50–7,797.50) | (4,760.00–7,525.00) | | (7,072.50–10,437.50) | (6,610.00–10,425.00) | | |
| ESR, mm/hr         | 21.50      | 13.50      | 0.087   | 71.50      | 39.00      | 0.005^a | < 0.001^a              | < 0.001^a   | < 0.001^a   |
|                    | (9.50–35.75) | (6.25–28.75) | | (38.50–90.50) | (16.75–73.25) | | |
| CRP, mg/L          | 3.50       | 3.50       | 0.660   | 9.25       | 7.75       | 0.173   | < 0.001^a              | < 0.001^a   | 0.831      |
|                    | (1.50–5.50) | (1.00–6.50) | | (5.00–9.50) | (4.50–11.50) | | |
| Ca, mg/dL          | 9.30       | 9.30       | 0.716   | 4.25       | 4.25       | 0.999   | < 0.001^a              | 0.010^a     | 0.777      |
|                    | (9.03–9.30) | (9.00–9.38) | | (3.80–4.85) | (4.18–4.93) | | |
| P, mg/dL           | 4.40       | 4.40       | 0.494   | 3.50       | 3.50       | 0.001^a | < 0.001^a              | 0.023^a     |
|                    | (4.03–4.50) | (4.03–4.60) | | (3.03–3.80) | (3.70–4.50) | | |
| Albumin, g/dL      | 209.50     | 200.00     | 0.066   | 133.00     | 172.00     | 0.066   | < 0.001^a              | 0.002^a     | 0.005^a    |
|                    | (175.50–217.75) | (200.50–290.50) | | (92.00–167.00) | (156.50–215.50) | | |
| Pre-albumin, mg/L  | 8.14       | 10.60      | 0.042^a | 7.66       | 7.96       | 0.938   | < 0.001^a              | 0.173       | 0.022^a    |
|                    | (5.81–10.33) | (7.97–7.29) | | (5.00–10.40) | (6.26–11.63) | | |
| Folate, ng/mL      | 68.00      | 78.60      | < 0.001^a | 7.20       | 7.90       | 0.148   | 0.056                  | 0.004^a     |
|                    | (68.00–86.18) | (78.60–101.90) | | (59.95–80.90) | (68.70–88.03) | | |
| Vitamin B12, pg/mL | 4.30       | 4.20       | 0.716   | 4.25       | 4.25       | 0.999   | < 0.001^a              | < 0.001^a   | 0.064      |
|                    | (4.11–4.50) | (3.80–4.85) | | (3.80–4.85) | (4.18–4.93) | | |
| Zinc, mcg/dL       | 74.90      | 87.75      | < 0.001^a | 72.80      | 79.90      | 0.148   | 0.056                  | 0.004^a     |
|                    | (68.00–86.18) | (78.60–101.90) | | (59.95–80.90) | (68.70–88.03) | | |
| Serum 25[OH]D, ng/mL | 17.50   | 19.36      | 0.348   | 12.41      | 12.51      | 0.611   | < 0.001^a              | 0.026^a     |
|                    | (12.70–20.42) | (10.99–23.82) | | (8.83–15.32) | (7.44–19.73) | | |

Values are presented as median (interquartile range).

CD = Crohn’s disease, UC = ulcerative colitis, WBC = white blood cell, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, Ca = calcium, P = phosphorus.

^aP value < 0.05, statistically significant.
DISCUSSION

Many studies have been conducted on malnutrition and micronutrient deficiencies due to the reduction of oral intake and increased gastrointestinal losses of nutrients in patients with IBD. Several studies have reported micronutrient deficiency in IBD and analyzed the relationship between nutritional deficiency and body mass index or body fat in IBD patients.

Especially many studies have conducted regarding vitamin D in IBD and some reports suggested that vitamin D regulates the secretion and inhibition of cytokines involved in the inflammatory response in immune systems as well as Ca homeostasis. Therefore,
it is important to supplement vitamin D and micronutrients in the treatment of IBD.\textsuperscript{19,20} However, these malnutrition and micronutrient deficiencies have not been studied in pediatric patients with IBD, even though these patients should be treated immediately to prevent adverse effects on their growth and development.

Our study showed that inflammatory markers, e.g., WBC, ESR, and CRP, are more elevated in CD than in UC, and this tendency was observed in the active and remission phases. Ca, P, and albumin were not significantly affected by disease activity in UC, whereas they remained significantly lower in the active phase than in the remission phase of CD and recovered well at the time of remission. In patients with UC and CD, folate and zinc levels showed a correlation with disease activity. They decreased in the active phase and increased in the remission phase. It is thought that IBD, especially CD, involving the small intestine, which is the site of folate and zinc absorption, affects the terminal ileum and increases folate and zinc deficiencies.\textsuperscript{21-23}

Interestingly, our study showed that vitamin B12 was higher in the active phase than in the remission phase. This finding is different from results of other studies in which micronutrients were found to be lower in the active phase of CD and recovered well at the time of remission. In patients with UC and CD, folate and zinc levels showed a correlation with disease activity. They decreased in the active phase and increased in the remission phase. It is thought that IBD, especially CD, involving the small intestine, which is the site of folate and zinc absorption, affects the terminal ileum and increases folate and zinc deficiencies.\textsuperscript{21-23}

Our results confirmed the findings of previous studies that reported a high prevalence of vitamin D deficiency in IBD.\textsuperscript{26,27} Although the mechanism is still unclear, vitamin D deficiency may be associated with an increased IBD activity score, lower sun exposure, and decreased absorption from inflammatory mucosa.\textsuperscript{18,28,29} In our study, the vitamin D level was higher in the remission phase than in the active phase in UC and CD. The reason for the increased vitamin D level in the remission is unclear, but is probably a result of a combination of increased nutritional intake, increased outdoor activity and reduced need for steroid
Because previous studies have suggested that steroids may enhance inactivation of 25\[OH\]D by promoting 24-hydroxylase activity. Also, as the disease improves, increased level of vitamin D will help the inducing or maintaining of remission by improving anti-inflammatory and immune-mediated regulation. Indeed, our study show that vitamin D level was similar in those who did and did not have ileocecal valve resection. Bile acid, which is known to be involved in lipid-soluble vitamin absorption, is reabsorbed through ileum. These results indicate that vitamin D deficiency in IBD is mostly related with disease activity rather than decreased absorption due to inflammation of the small intestine. Therefore, in order to prevent various complications of vitamin D deficiency, it is important to maintain a prolonged remission state by controlling the activity of IBD.

Compared to other micronutrients, vitamin D levels tended to show a larger difference depending on disease activity. This result suggests that vitamin D deficiency itself in IBD may lead to disease aggravation. Recent studies have shown that vitamin D is involved in the immune system and inflammatory response by inhibiting the regulation of inflammatory cytokines and differentiation of proinflammatory cells. Further, other studies demonstrated an experimental link between vitamin D status and severity of IBD in animals: vitamin D deficiency exacerbated the symptoms and severity of enterocolitis in interleukin-10 knockout mice, whereas supplementation with vitamin D ameliorated IBD symptoms, reduced inflammation, and improved histologic scores and mortality.

According to Garg et al., fecal leukocytes (e.g., calprotectin) more closely reflect intestinal inflammation than systemic markers (e.g., CRP, ESR, and WBC). They also reported an inverse correlation between the levels of vitamin D and calprotectin in patients with IBD. These findings support the theory that serum 25\[OH\]D may affect local tissue inflammation. Thus, vitamin D supplementation may need to be studied as a drug for regulating IBD inflammation and providing nutritional support.

In our study, patients in the active phase showed seasonal variation, with decreasing vitamin D levels in spring and winter. However, there was no significant difference by season in the remission phase, suggesting that patients in the active phase are more sensitive to seasonal factors.

There are limitations to our investigation. First, this study had a retrospective design and was performed in a single center with a small sample of patients. Second, the effects of sun exposure, dietary or over the counter vitamin D supplementation could not be measured accurately. In Korea, there is little exposure to sunlight between 33°N and 43°N, and there is not enough difference in available sunlight by season. Third, many patients lacked sufficient available endoscopic findings in order for us to investigate the association between vitamin D status and the degree of inflammation. Lastly, this study lacked bone mass densitometry study results and fecal calprotectin levels for most patients.

In conclusion, malnutrition and micronutrient deficiencies are common in IBD. Especially, vitamin D deficiency showed the greatest difference according to IBD activity, and it may be related to intestinal absorption as well as medication and sun exposure. IBD itself may affect vitamin D deficiency, and a low vitamin D level may aggravate the inflammatory response of IBD. Lack of micronutrients, including vitamin D, can lead to worsening of IBD and cause irreversible sequelae in growing children; therefore, it is important to prevent and correct vitamin D deficiency as soon as possible. In the future, it will be important to monitor the
vitamin D level more carefully in the active phase, spring, and winter in Korean pediatric patients with IBD and to provide sufficient vitamin D supplementation if there is a deficiency.

REFERENCES

1. Kabbani TA, Koutroubakis IE, Schoen RE, Ramos-Rivers C, Shah N, Swoger J, et al. Association of vitamin D level with clinical status in inflammatory bowel disease: a 5-year longitudinal study. *Am J Gastroenterol* 2016;111(5):712-9.

2. Limketkai BN, Mullin GE, Limsui D, Parian AM. Role of vitamin D in inflammatory bowel disease. *Nutr Clin Pract* 2017;32(3):337-45.

3. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. *Inflamm Bowel Dis* 2006;12 Suppl 1:S3-9.

4. Weisshof R, Chermesh I. Micronutrient deficiencies in inflammatory bowel disease. *Curr Opin Clin Nutr Metab Care* 2015;18(6):576-81.

5. Ogura Y, Bonen DK, Inohara N, Nicolel DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. *Nature* 2001;411(6857):603-6.

6. Munger KL, Zhang SM, O'Reilly E, Hernán MA, Olek MJ, Willett WC, et al. Vitamin D intake and incidence of multiple sclerosis. *Neurology* 2004;62(1):60-5.

7. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. *Autoimmun Rev* 2006;5(2):114-7.

8. Mouli VP, Ananthakrishnan AN. Vitamin D and inflammatory bowel diseases. *Aliment Pharmacol Ther* 2014;39(2):125-36.

9. Ananthakrishnan AN. Vitamin D and inflammatory bowel disease. *Gastroenterol Hepatol (N Y)* 2016;12(8):513-5.

10. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. *Lancet* 1998;351(9105):805-6.

11. Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;357(3):266-81.

12. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *Am J Clin Nutr* 2006;84(1):18-28.

13. Goh J, O’Morain CA. Nutrition and adult inflammatory bowel disease. *Aliment Pharmacol Ther* 2003;17(3):307-20.

14. Lupu A, Diculescu M, Diaconescu R, Tantau M, Tantau A, Visovan I, et al. Prevalence of anemia and iron deficiency in Romanian patients with inflammatory bowel disease: a prospective multicenter study. *J Gastrointestin Liver Dis* 2015;24(1):15-20.

15. Cortes X, Borrás-Blasco J, Molés IR, Boscá M, Cortés E. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study. *PLoS One* 2015;10(5):e0128156.

16. Cantorna MT, Zhu Y, Froicu M, Witterte A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. *Am J Clin Nutr* 2004;80(6 Suppl):171S-1720S.

17. Cantorna MT, Mahon BD. D-hormone and the immune system. *J Rheumatol Suppl* 2005;76:11-20.
18. Ulitsky A, Ananthakrishnan AN, Naik A, Skaros S, Zadvornova Y, Binion DG, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. *JPEN J Parenter Enteral Nutr* 2011;35(3):308-46.

19. Ghishan FK, Kjela PR. Vitamins and Minerals in Inflammatory Bowel Disease. *Gastroenterol Clin North Am* 2017;46(4):797-808.

20. Fernandez-Banares F, Abad-Lacruz A, Xiol X, Gine IJ, Dolz C, Cabre E, et al. Vitamin status in patients with inflammatory bowel disease. *Am J Gastroenterol* 1989;84(7):744-8.

21. Bermejo F, Algaba A, Guerra I, Chaparro M, De-La-Pozas G, Valer P, et al. Should we monitor vitamin B12 and folate levels in Crohn’s disease patients? *Scand J Gastroenterol* 2013;48(11):1272-7.

22. Bermejo F, Algaba A, Guerra I, Gisbert JP. Response to letter: folate deficiency in Crohn’s disease. *Scand J Gastroenterol* 2014;49(2):255-6.

23. Santucci NR, Alkhouri RH, Baker RD, Baker SS. Vitamin and zinc status pretreatment and posttreatment in patients with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2014;59(4):455-7.

24. Battar T, Kopylov U, Szilagyi A, Saxena A, Rosenblatt DS, Warner M, et al. Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management. *Inflamm Bowel Dis* 2014;20(6):1120-8.

25. Sentongo TA, Semaeo EJ, Stettler N, Piccoli DA, Stallings VA, Zemel BS. Vitamin D status in children, adolescents, and young adults with Crohn disease. *Am J Clin Nutr* 2002;76(5):1077-81.

26. de Bruyn JR, van Heeckeren R, van den Brink GR, Löwenberg M, Bredenoord AI, et al. Vitamin D deficiency in Crohn’s disease and healthy controls: a prospective case-control study in the Netherlands. *J Crohns Colitis* 2014;8(10):1267-73.

27. Blanck S, Aberra F. Vitamin d deficiency is associated with ulcerative colitis disease activity. *Dig Dis Sci* 2013;58(6):1698-702.

28. Torki M, Gholamrezaei A, Mirbagher L, Danesh M, Kheiri S, Emami MH. Vitamin D Deficiency Associated with Disease Activity in Patients with Inflammatory Bowel Diseases. *Dig Dis Sci* 2015;60(10):3085-91.

29. Dhawan P, Christakos S. Novel regulation of 25-hydroxyvitamin D3 24-hydroxylase (24(OH)ase) transcription by glucocorticoids: cooperative effects of the glucocorticoid receptor, C/EBPβ, and the Vitamin D receptor in 24(OH)ase transcription. *J Cell Biochem* 2010;110(6):1314-23.

30. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. *Am J Clin Nutr* 2004;80(6 Suppl):1678S-1688S.

31. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. *Exp Biol Med (Maywood)* 2004;229(11):1136-42.

32. Garg M, Rosell O, Lube JS, Gibson PR. Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. *Inflamm Bowel Dis* 2013;19(12):2634-43.